[Mutations in the BCR-ABL1 gene in a peruvian patient with acute lymphoblastic leukemia resistant to therapy]. / Mutaciones en el gen BCR-ABL1 en un paciente peruano con leucemia linfoblástica aguda resistente a terapia.
Rev Fac Cien Med Univ Nac Cordoba
; 74(2): 162-166, 2017.
Article
em Es
| MEDLINE
| ID: mdl-28657534
CONTEXT: The fusion gene BCR-ABL1 is present in at least the fourth part of B-cell acute lymphoblastic leukemia adult cases. Patients with this fusion gene are candidates to tyrosine kinase inhibitors treatment, and the response to this therapy can be measure by quantification of BCR-ABL1 transcripts. Some patients relapse because the presence of mutations in the tyrosine kinase domain of BCR-ABL1. CASE REPORT: This is a report of a patient with BCR-ABL1 who initially achieved molecular response with imatinib therapy, relapsing after fifteen months. The treatment was changed to dasatinib, but the patient doesn't achieve molecular response. Retrospectively, we analyzed the tyrosine kinase domain of BCR-ABL1 and we found three mutations (E459K, E255K and V299L). CONCLUSIONS: We conclude that gain of mutations during treatment with TKIs has strong impact in the progress of disease, being relevant the detection of BCR-ABL1 mutations in relapsed patients or in case of BCR-ABL1 persistence.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Biomarcadores Tumorais
/
Proteínas de Fusão bcr-abl
/
Leucemia-Linfoma Linfoblástico de Células Precursoras
/
Mutação
Limite:
Adult
/
Female
/
Humans
País/Região como assunto:
America do sul
/
Peru
Idioma:
Es
Revista:
Rev Fac Cien Med Univ Nac Cordoba
Ano de publicação:
2017
Tipo de documento:
Article
País de publicação:
Argentina